Acute malignant obstruction in patients with peritoneal carcinomatosis: The role of palliative surgery

Patients with peritoneal carcinomatosis who do not have curative treatment options often develop acute obstructive symptoms and when conservative management fails, surgical treatment is the remaining option. However, palliative surgery is associated with high morbidity and mortality and the chance o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of surgical oncology 2019-03, Vol.45 (3), p.389-393
Hauptverfasser: de Boer, Nadine L., Hagemans, Jan A.W., Schultze, Bob T.A., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Verhoef, Cornelis, Burger, Jacobus W.A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with peritoneal carcinomatosis who do not have curative treatment options often develop acute obstructive symptoms and when conservative management fails, surgical treatment is the remaining option. However, palliative surgery is associated with high morbidity and mortality and the chance of success is unclear. The aim of this study was to evaluate outcomes of palliative surgery and to provide guidance for surgeons, medical oncologists and patients in their decision-making. All consecutive patients who underwent palliative surgery for acute obstruction caused by peritoneal carcinomatosis between January 2005 and October 2017 where identified. In total 148 patients underwent surgery. Primary malignancy was colorectal cancer (28.4%), neuroendocrine tumor (20.3%), ovarian cancer (14.2%) or ‘other’ (37.2%). Median length of postoperative hospital stay was 16 days (IQR 9–24). More than half (58.1%) of the patients developed postoperative complications, 29.1% developed ≥2 complications. In-hospital mortality was 8.8%. Readmission (56.1%) and re-obstruction (35.0%) were common. Median overall survival was 119 days (IQR 48–420). Patients with a neuroendocrine tumor had a significantly better overall survival compared to other primary malignancies (p 
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2018.12.015